Evaxion reports new data supporting EVX-04 vaccine for acute myeloid leukemia
EVAX•Evaxion will present preclinical data on its EVX-04 vaccine at ASH in New Orleans on December 12-15, 2026, including findings of broad patient coverage, consistent target expression and target-specific immune responses in humanized mice.
1. Preclinical findings
Evaxion will present new preclinical data on EVX-04, its off-the-shelf acute myeloid leukemia vaccine, at ASH in New Orleans on December 12-15, 2026. The findings support broad patient coverage and consistent target expression across disease stages, and the vaccine induced target-specific immune responses in humanized mice.
2. Earlier results
The new findings build on data presented at ASH 2025 showing vaccine-specific immune responses and tumor growth inhibition in mouse models.
